Literature DB >> 19109818

Radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2: tumor control and hearing preservation.

Ji Hoon Phi1, Dong Gyu Kim, Hyun-Tai Chung, Joongyub Lee, Sun Ha Paek, Hee-Won Jung.   

Abstract

BACKGROUND: The radiosurgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2 (NF2) is controversial. The authors investigated the radiologically proven tumor control rate after gamma knife radiosurgery. The factors that affect tumor control and serviceable hearing preservation were analyzed.
METHODS: Thirty-six lesions in 30 patients were included. The median lengths of the clinical and radiologic follow-ups were 48.5 months and 36.5 months, respectively. The median tumor volume was 3.2 cm3. The mean marginal dose was 12.1 grays (Gy) (range, 8-14 Gy) at an isodose line of 50%+/-0.6%. The Kaplan-Meier method and Cox proportional hazards model were used for the statistical analyses.
RESULTS: The actuarial tumor control rate was 81%, 74%, and 66%, respectively, in the first, second, and fifth years. Five tumors required a salvage surgery because of tumor control failure. A low marginal dose and a young age at radiosurgery were associated with poor tumor control. Of the 16 tumors with which ipsilateral hearing was serviceable, the actuarial serviceable hearing preservation rates were 50%, 45%, and 33%, respectively, in the first, second, and fifth years. Better ipsilateral hearing (Gardner-Robertson grade 1, compared with grade 2) at the time of radiosurgery was associated with significantly greater serviceable hearing preservation.
CONCLUSIONS: Gamma knife radiosurgery for vestibular schwannomas in NF2 patients provided 5-year tumor control in approximately two-thirds of patients and preserved serviceable hearing in approximately one-third. The rates of other cranial nerve deficits were low, and no secondary malignancy was observed. Radiosurgery should be included in treatment options for NF2 patients. Copyright (c) 2009 American Cancer Society.

Entities:  

Mesh:

Year:  2009        PMID: 19109818     DOI: 10.1002/cncr.24036

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  Description of selected characteristics of familial glioma patients - results from the Gliogene Consortium.

Authors:  Siegal Sadetzki; Revital Bruchim; Bernice Oberman; Georgina N Armstrong; Ching C Lau; Elizabeth B Claus; Jill S Barnholtz-Sloan; Dora Il'yasova; Joellen Schildkraut; Christoffer Johansen; Richard S Houlston; Sanjay Shete; Christopher I Amos; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Daniel Lachance; Nicholas A Vick; Ryan Merrell; Margaret Wrensch; Faith G Davis; Bridget J McCarthy; Rose Lai; Beatrice S Melin; Melissa L Bondy
Journal:  Eur J Cancer       Date:  2013-01-04       Impact factor: 9.162

2.  Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas.

Authors:  Ramita Dewan; Alex Pemov; H Jeffrey Kim; Keaton L Morgan; Raul A Vasquez; Prashant Chittiboina; Xiang Wang; Settara C Chandrasekharappa; Abhik Ray-Chaudhury; John A Butman; Douglas R Stewart; Ashok R Asthagiri
Journal:  Neuro Oncol       Date:  2014-12-01       Impact factor: 12.300

3.  Progress of hearing loss in neurofibromatosis type 2: implications for future management.

Authors:  Georgios Kontorinis; Jaya Nichani; Simon R Freeman; Scott A Rutherford; Samantha Mills; Andrew T King; Deborah Mawman; Sue Huson; Martin O'Driscoll; D Gareth Evans; Simon K W Lloyd
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-08       Impact factor: 2.503

4.  Increased growth rate of vestibular schwannoma after resection of contralateral tumor in neurofibromatosis type 2.

Authors:  Matthieu Peyre; Stephane Goutagny; Sandrine Imbeaud; Alexis Bozorg-Grayeli; Michele Felce; Olivier Sterkers; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2011-07-28       Impact factor: 12.300

5.  Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2.

Authors:  Manish Singh Sharma; Rakesh Singh; Shashank S Kale; Deepak Agrawal; Bhawani Shankar Sharma; Ashok Kumar Mahapatra
Journal:  J Neurooncol       Date:  2010-04-20       Impact factor: 4.130

Review 6.  CNS Tumors in Neurofibromatosis.

Authors:  Jian Campian; David H Gutmann
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

7.  The efficacy of lapatinib and nilotinib in combination with radiation therapy in a model of NF2 associated peripheral schwannoma.

Authors:  Iddo Paldor; Sara Abbadi; Nicolas Bonne; Xiaobu Ye; Fausto J Rodriguez; David Rowshanshad; MariaLisa Itzoe; Veronica Vigilar; Marco Giovannini; Henry Brem; Jaishri O Blakeley; Betty M Tyler
Journal:  J Neurooncol       Date:  2017-07-22       Impact factor: 4.130

Review 8.  Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Authors:  Scott R Plotkin; Chris Halpin; Jaishri O Blakeley; William H Slattery; D Bradley Welling; Susan M Chang; Jay S Loeffler; Gordon J Harris; A Gregory Sorensen; Michael J McKenna; Fred G Barker
Journal:  J Neurooncol       Date:  2009-05-09       Impact factor: 4.130

9.  Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients: a systematic review and meta-analysis.

Authors:  Umberto Tosi; Omri Maayan; Anjile An; Miguel E Tusa Lavieri; Sergio W Guadix; Antonio P DeRosa; Paul J Christos; Susan Pannullo; Philip E Stieg; Andrew Brandmaier; Jonathan P S Knisely; Rohan Ramakrishna
Journal:  J Neurooncol       Date:  2022-01-18       Impact factor: 4.130

Review 10.  The Neurofibromatoses.

Authors:  Said Farschtschi; Victor-Felix Mautner; Anna Cecilia Lawson McLean; Alexander Schulz; Reinhard E Friedrich; Steffen K Rosahl
Journal:  Dtsch Arztebl Int       Date:  2020-05-15       Impact factor: 5.594

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.